DOI QR코드

DOI QR Code

Anticancer Therapy for Breast Cancer Patients with Skin Metastases Refractory to Conventional Treatments

  • Varol, Umut (Medical Oncology Clinic, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Yildiz, Ibrahim (Medical Oncology Clinic, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Alacacioglu, Ahmet (Medical Oncology Clinic, Izmir Katip Celebi University Ataturk Training and Research Hospital) ;
  • Uslu, Ruchan (Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University)
  • Published : 2014.02.28

Abstract

Skin metastases of breast cancer are usually late events in the course of tumor progression and signify a poor prognosis. They may remain as a therapeutic challenge especially after failure of standard treatments. Topical interventions, together with or without radiotherapy, may only palliate the symptoms temporarily. However, there may be alternative treatment modalities for unresectable breast cancer skin metastases resistant to chemotherapy and radiotherapy. There are various genetic alterations in tumors and therapeutic potential of expression patterns for factors like epidermal growth factor receptor may have important clinical implications in case of disease refractory to the conventional treatments. Here, we clarified the therapeutic options and genetic alterations in skin metastatic breast cancer patients refractory to standard chemotherapeutics.

Keywords

Anticancer therapy;breast cancer;skin metastases;refractory

References

  1. Adams S, Kozhaya L, Martiniuk F, et al (2012). Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res, 18, 6748-57. https://doi.org/10.1158/1078-0432.CCR-12-1149
  2. Andre F, Cabioglu N, Assi H, et al (2006). Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol, 17, 945-51. https://doi.org/10.1093/annonc/mdl053
  3. Sideras K, Zahasky KM, Kaur JS (2008). Response of cutaneous metastases from breast cancer to capecitabine. Clin Med Oncol, 2, 415-8.
  4. Sihto H, Lundin J, Lundin M, et al (2011). Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res, 13, 87. https://doi.org/10.1186/bcr2944
  5. Smorenburg CH, Seynaeve C, Bontenbal M, et al (2000). Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs, 11, 825-8. https://doi.org/10.1097/00001813-200011000-00006
  6. Tokugawa T, Kobayashi A, Okubo K, et al (2009). A patient with multiple skin metastases from breast cancer responding to S-1 effectively under treatment with trastuzumab. Gan To Kagaku Ryoho, 36, 679-82.
  7. Wollina U (2012). Cetuximab in non-melanoma skin cancer. Expert Opin Biol Ther, 12, 949-56. https://doi.org/10.1517/14712598.2012.681374
  8. Kouloulias VE, Plataniotis GA, Kouvaris JR, et al (2003). Reirradiation in conjunction with liposomal doxorubicin for the treatment of skin metastases of recurrent breast cancer: a radiobiological approach and 2 year of follow-up. Cancer Lett, 193, 33-40. https://doi.org/10.1016/S0304-3835(02)00742-5
  9. Ihnen M, Kilic E, Kohler N, et al (2011). Protein expression analysis of ALCAM and CEACAM6 in breast cancer metastases reveals significantly increased ALCAM expression in metastases of the skin. J Clin Pathol, 64, 146-52. https://doi.org/10.1136/jcp.2010.082602
  10. Kurebayashi J, Otsuki T, Kunisue H, et al (1999). Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res, 90, 977-81. https://doi.org/10.1111/j.1349-7006.1999.tb00844.x
  11. Kong JH, Park YH, Kim JA, et al (2011). Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations. Oncology, 81, 55-62. https://doi.org/10.1159/000331417
  12. Mader RM, Schrolnberger C, Rizovski B, et al (2003). Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer. Br J Cancer, 88, 782-7. https://doi.org/10.1038/sj.bjc.6600809
  13. Ng EH, Pey HB, Law HY, et al (1997). Loss of c-met protooncogene in primary and metastatic sites of breast cancer. Ann Surg Oncol, 4, 499-502. https://doi.org/10.1007/BF02303675
  14. Tsuyuki S, Kawaguchisakita N, Tsubota Y, Ukikusa M, Kohno Y (2010). More effective positioning of capecitabine for advanced and metastatic breast cancer. Gan To Kagaku Ryoho, 37, 649-53.
  15. Rebersek M, Cufer T, Cemazar M, Kranjc S, Sersa G (2004). Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs, 15, 593-7. https://doi.org/10.1097/01.cad.0000132234.30674.df
  16. Rochlitz CF, Scott GK, Dodson JM, et al (1989). Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res, 49, 357-60.
  17. Franchina T, Adamo B, Ricciardi GR, et al (2012). Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. Cancer Biol Ther, 13, 472-6. https://doi.org/10.4161/cbt.19593
  18. Colpaert CG, Vermeulen PB, Van Beest P, et al (2003). Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology, 42, 530-40. https://doi.org/10.1046/j.1365-2559.2003.01629.x
  19. Coskun U, Gunel N, Yamac D, Altinova AE (2011). Effect of cisplatin on skin metastasis in breast cancer patients. Onkologie, 24, 576-9.
  20. Cottu PH, Fourchotte V, Vincent-Salomon A, Kriegel I, Fromantin I (2011). Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy. J Wound Care, 20, 403-4. https://doi.org/10.12968/jowc.2011.20.9.403
  21. Fritz P, Hensley FW, Berns C, Harms W, Wannenmacher M (2000). Long-term results of pulsed irradiation of skin metastases from breast cancer. Effectiveness and sequelae. Strahlenther Onkol, 176, 368-76. https://doi.org/10.1007/PL00002345
  22. Gholam D, Chebib A, Hauteville D, Bralet MP, Jasmin C (2007). Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. Anticancer Drugs, 18, 835-7. https://doi.org/10.1097/CAD.0b013e3280adc8e0
  23. Hachisuka J, Doi K, Furue M (2012). Combination cryosurgery with hyperthermia in the management of skin metastasis from breast cancer: A case report. Int J Surg Case Rep, 3, 68-9. https://doi.org/10.1016/j.ijscr.2011.10.016
  24. Hirao A, Oiso N, Tsurutani J, et al (2011). Transient effectiveness of an oral 5-Fluorouracil derivative, s-1, for epirubicin, cyclophosphamide and Paclitaxel refractory skin metastases from possible occult breast cancer in a male. Case Rep Dermatol, 3, 42-8.

Cited by

  1. Fungal Taxol Extracted from Cladosporium oxysporum Induces Apoptosis in T47D Human Breast Cancer Cell Line vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6627